Equities Analysts Issue Forecasts for Abivax FY2027 Earnings

Key Points

• Abivax's FY2027 EPS estimates were revised by Leerink Partners from ($3.41) to ($3.40), indicating a slight improvement in expected losses.
• Analyst ratings on Abivax show mixed opinions, with one Strong Buy and eight Buy ratings but a contrasting Sell rating from Weiss Ratings, reflecting varied investor sentiment.
• Abivax's stock performance has seen significant volatility, with a 52-week low of $4.77 and a high of $92.91, indicating a dynamic trading environment for the stock.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) - Stock analysts at Leerink Partnrs upped their FY2027 earnings per share (EPS) estimates for Abivax in a note issued to investors on Monday, October 6th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($3.40) for the year, up from their previous forecast of ($3.41). The consensus estimate for Abivax's current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Abivax's FY2028 earnings at ($2.06) EPS and FY2029 earnings at $2.95 EPS.

ABVX has been the topic of a number of other research reports. Morgan Stanley raised their price objective on shares of Abivax from $71.00 to $101.00 and gave the company an "overweight" rating in a research note on Friday, September 12th. Citigroup reaffirmed an "outperform" rating on shares of Abivax in a research note on Thursday, September 25th. Piper Sandler lifted their price target on shares of Abivax from $70.00 to $112.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 29th. Guggenheim lifted their target price on Abivax from $50.00 to $101.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Abivax in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Abivax has an average rating of "Moderate Buy" and a consensus target price of $103.29.

Abivax Price Performance

Abivax stock opened at $86.51 on Thursday. Abivax has a 52 week low of $4.77 and a 52 week high of $92.91. The company's 50-day moving average price is $79.39 and its two-hundred day moving average price is $34.46.

Abivax (NASDAQ:ABVX - Get Free Report) last posted its earnings results on Monday, September 8th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.04.

Institutional Investors Weigh In On Abivax

Several institutional investors have recently made changes to their positions in ABVX. Bank of America Corp DE lifted its stake in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after acquiring an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock worth $63,000 after buying an additional 2,595 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Abivax by 373.6% in the 1st quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock worth $118,000 after purchasing an additional 14,855 shares during the last quarter. XTX Topco Ltd acquired a new stake in Abivax in the 2nd quarter worth approximately $139,000. Finally, Two Sigma Investments LP acquired a new stake in Abivax in the 4th quarter worth approximately $144,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.